» Articles » PMID: 34192089

Unraveling the SARS-CoV-2 Main Protease Mechanism Using Multiscale Methods

Overview
Journal ACS Catal
Date 2021 Jun 30
PMID 34192089
Citations 53
Authors
Affiliations
Soon will be listed here.
Abstract

We present a detailed theoretical analysis of the reaction mechanism of proteolysis catalyzed by the main protease of SARS-CoV-2. Using multiscale simulation methods, we have characterized the interactions established by a peptidic substrate in the active site, and then we have explored the free energy landscape associated with the acylation and deacylation steps of the proteolysis reaction, characterizing the transition states of the process. Our mechanistic proposals can explain most of the experimental observations made on the highly similar ortholog protease of SARS-CoV. We point to some key interactions that may facilitate the acylation process and thus can be crucial in the design of more specific and efficient inhibitors of the main protease activity. In particular, from our results, the P1' residue can be a key factor to improve the thermodynamics and kinetics of the inhibition process.

Citing Articles

Exploring covalent inhibitors of SARS-CoV-2 main protease: from peptidomimetics to novel scaffolds.

Atatreh N, Mahgoub R, Ghattas M J Enzyme Inhib Med Chem. 2025; 40(1):2460045.

PMID: 39912405 PMC: 11803818. DOI: 10.1080/14756366.2025.2460045.


Catalytic Mechanism of SARS-CoV-2 3-Chymotrypsin-Like Protease as Determined by Steady-State and Pre-Steady-State Kinetics.

Zhu J, Kemp A, Chenna B, Kumar V, Rademacher A, Yun S ACS Catal. 2024; 14(24):18292-18309.

PMID: 39722883 PMC: 11667672. DOI: 10.1021/acscatal.4c04695.


3-Chymotrypsin-like Protease (3CLpro) of SARS-CoV-2: Validation as a Molecular Target, Proposal of a Novel Catalytic Mechanism, and Inhibitors in Preclinical and Clinical Trials.

Amorim V, Soares E, de Almeida Ferrari A, Merighi D, de Souza R, Guzzo C Viruses. 2024; 16(6).

PMID: 38932137 PMC: 11209289. DOI: 10.3390/v16060844.


Sensitive detection of SARS-CoV-2 main protease 3CL with an engineered ribonuclease zymogen.

Wralstad E, Raines R Protein Sci. 2024; 33(4):e4916.

PMID: 38501598 PMC: 10949392. DOI: 10.1002/pro.4916.


Bioengineered amyloid peptide for rapid screening of inhibitors against main protease of SARS-CoV-2.

Lee D, Jung H, Park D, Bang J, Cheong D, Jang J Nat Commun. 2024; 15(1):2108.

PMID: 38453923 PMC: 10920794. DOI: 10.1038/s41467-024-46296-7.